434 related articles for article (PubMed ID: 11439092)
1. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
[TBL] [Abstract][Full Text] [Related]
3. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Ramaswamy S; Nakamura N; Vazquez F; Batt DB; Perera S; Roberts TM; Sellers WR
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2110-5. PubMed ID: 10051603
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
6. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
[TBL] [Abstract][Full Text] [Related]
7. 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Taylor V; Wong M; Brandts C; Reilly L; Dean NM; Cowsert LM; Moodie S; Stokoe D
Mol Cell Biol; 2000 Sep; 20(18):6860-71. PubMed ID: 10958682
[TBL] [Abstract][Full Text] [Related]
8. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.
Li DM; Sun H
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15406-11. PubMed ID: 9860981
[TBL] [Abstract][Full Text] [Related]
9. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.
Arico S; Petiot A; Bauvy C; Dubbelhuis PF; Meijer AJ; Codogno P; Ogier-Denis E
J Biol Chem; 2001 Sep; 276(38):35243-6. PubMed ID: 11477064
[TBL] [Abstract][Full Text] [Related]
10. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
[TBL] [Abstract][Full Text] [Related]
11. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Wu X; Senechal K; Neshat MS; Whang YE; Sawyers CL
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15587-91. PubMed ID: 9861013
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
[TBL] [Abstract][Full Text] [Related]
13. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
14. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.
Dahia PL; Aguiar RC; Alberta J; Kum JB; Caron S; Sill H; Marsh DJ; Ritz J; Freedman A; Stiles C; Eng C
Hum Mol Genet; 1999 Feb; 8(2):185-93. PubMed ID: 9931326
[TBL] [Abstract][Full Text] [Related]
15. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
16. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
17. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.
Vazquez F; Sellers WR
Biochim Biophys Acta; 2000 Feb; 1470(1):M21-35. PubMed ID: 10656987
[No Abstract] [Full Text] [Related]
18. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
19. Enhanced protein kinase B/Akt signalling in pituitary tumours.
Musat M; Korbonits M; Kola B; Borboli N; Hanson MR; Nanzer AM; Grigson J; Jordan S; Morris DG; Gueorguiev M; Coculescu M; Basu S; Grossman AB
Endocr Relat Cancer; 2005 Jun; 12(2):423-33. PubMed ID: 15947113
[TBL] [Abstract][Full Text] [Related]
20. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
